 Home > Biochemistry News > Biotechnology News > Cinda launches PD-1 adjuvant/neo-adjuvant treatment of NSCLC large-scale international multi-center phase III clinical trial

Cinda launches PD-1 adjuvant/neo-adjuvant treatment of NSCLC large-scale international multi-center phase III clinical trial

 Last Update: 2021-12-02
 Source: Internet
 Author: User

Tags

double helix model

people

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On November 12, Cinda Bioregistered and initiated a large international multi-center phase III clinical ORIENT-99 study of sintilimab combined with chemotherapy for preoperative neoadjuvant and postoperative adjuvant treatment of non-small cell lung cancer

Last week, immunotherapy has just ushered in the first phase III positive result in the field of neoadjuvant treatment of non-small cell lung cancer: nivolumab achieved EFS (event-free survival) + pCR (pathological complete remission) in the Checkmate-816 study ) Double positive result

ORIENT-99 clinical trial registration

From Insight database (http://db.

ORIENT-99 is the effectiveness and safety of sintilimab combined with chemotherapy or placebo combined with chemotherapy before surgery and sintilimab or placebo after surgery for resectable non-small cell lung cancer.

At present, immunotherapy has gradually captured the front-line to the back-line treatment of major cancers, and adjuvant therapy and neoadjuvant therapy have become a new battlefield for immune checkpoint inhibitors led by PD-1/L1

Clinical registration of domestic PD-1/L1 adjuvant and neoadjuvant therapy

*As of November 9, 2021, only CDE source data is collected

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.